Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topoisomerase II cleavable complex formation within DNA loop domains.

J M Lambert1, D J Fernandes

  • 1Department of Experimental Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.

Biochemical Pharmacology
|May 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An analysis of response to neo-adjuvant chemotherapy in patients with locally advanced breast cancer with emphasis on pathological complete response.

Indian journal of cancer·2016
Same author

A rare case of primary Ewings sarcoma of the nasal bone.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India·2012
Same author

In vitro analysis of protection of the enzyme bile salt hydrolase against enteric conditions by whey protein-gum arabic microencapsulation.

Journal of agricultural and food chemistry·2008
Same author

Vibrational spectroscopy studies of formalin-fixed cervix tissues.

Biopolymers·2006
Same author

The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.

Pulmonary pharmacology & therapeutics·2005
Same author

Anti-remodelling drugs for the treatment of asthma: requirement for animal models of airway wall remodelling.

Clinical and experimental pharmacology & physiology·2001

VM-26 (Teniposide) stabilizes DNA cleavable complexes, primarily at nuclear matrix replication sites, inhibiting DNA synthesis by stalling replication forks. This mechanism is less effective in drug-resistant cells with reduced topoisomerase IIalpha.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • VM-26 (Teniposide) is a topoisomerase II inhibitor used in cancer therapy.
  • Understanding its precise mechanism of DNA synthesis inhibition is crucial for optimizing its use.
  • The nuclear matrix plays a role in DNA replication and organization.

Purpose of the Study:

  • To investigate the distribution of VM-26-stabilized cleavable complexes within DNA loops bound to the nuclear matrix.
  • To elucidate the role of the nuclear matrix in VM-26-induced DNA synthesis inhibition.
  • To compare VM-26 activity in drug-sensitive and drug-resistant cancer cells.

Main Methods:

  • Quantification of covalent [(3)H]VM-26 binding to nuclear matrix and nonmatrix proteins.
  • Analysis of cleavable complex formation frequency in replicating and non-replicating DNA fractions.

Related Experiment Videos

  • Assessment of nascent DNA distribution in nuclear matrix and nonmatrix fractions following VM-26 treatment.

    • Main Results:

    • VM-26 showed significantly higher covalent binding to nuclear matrix proteins compared to nonmatrix proteins.
    • VM-26 induced a concentration-dependent increase in cleavable complexes on actively replicating matrix DNA.
    • Drug-resistant cells exhibited reduced cleavable complex formation and lower topoisomerase IIalpha levels in the nuclear matrix.

    Conclusions:

    • Nascent DNA associated with the nuclear matrix is a primary target for VM-26 cleavable complex formation.
    • VM-26 inhibits DNA synthesis by impeding nascent DNA movement away from nuclear matrix replication sites.
    • Differences in nuclear matrix-bound topoisomerase IIalpha contribute to VM-26 resistance.